Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced it has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases. The initial phase of this project, including the reporting of profiled data, is scheduled to complete by the end of calendar year 2021.
Under this agreement, Oncimmune will utilise its proprietary NavigAIDTM autoimmune disease characterisation panel to explore the autoantibody profiles of patients with four key autoimmune diseases, namely systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis and sicca syndrome. Oncimmune’s customised autoimmune disease panel has been developed to explore the mechanisms of action, disease stratification and response prediction in clinical trials.
The programme is Oncimmune’s second agreement with this global partner, and further validates the value of Oncimmune’s autoantibody biomarker profiling technology in supporting pharmaceutical and biotechnology companies in their clinical development programmes.
Dr Adam M Hill, CEO of Oncimmune Holdings, said: “We are delighted that this global pharmaceutical company has again chosen to partner with Oncimmune, for our world class autoantibody biomarker profiling technology and autoimmune expertise. We are confident that this latest programme will form part of a larger and long-term collaboration and we look forward to supporting their programmes in immunology further through clinical development.
“Today’s agreement further demonstrates the strength of our ImmunoINSIGHTS service, the increasing recognition of Oncimmune’s expertise in autoimmune disease, and our partnering strategy. This new contract is also a good illustration of the growing uptake of our services, validating our decision to invest in the physical and human infrastructure of our platform to increase capacity significantly, with further pipeline conversion expected over the coming months and beyond.”
